Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOncology: Clinical Therapy and Diagnosis

Predictors of outcome in patients with neuroendocrine neoplasm (NEN) undergoing FDG PET prior to PRRT

David Chan, Paul Roach, Elizabeth Bernard, Nick Pavlakis, Stephen Clarke, Kathy Willowson, Dale Bailey and Geoff Schembri
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1514;
David Chan
1Royal North Shore Hospital St Leonards Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Roach
3Royal North Shore Hospital St. Leonards Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elizabeth Bernard
1Royal North Shore Hospital St Leonards Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nick Pavlakis
2Royal North Shore Hospital Sydney Australia
4Royal North Shore Hospital Sydney Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Clarke
1Royal North Shore Hospital St Leonards Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathy Willowson
2Royal North Shore Hospital Sydney Australia
4Royal North Shore Hospital Sydney Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dale Bailey
5Department of Nuclear Medicine Royal North Shore Hospital Sydney Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Geoff Schembri
1Royal North Shore Hospital St Leonards Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1514

Background: 18-Fluorodeoxyglucose (FDG) PET avidity in NENs has been associated with higher grade disease. Avidity and high SUVmax have been demonstrated to predict poor outcome. Quantitative metrics of FDG PET, specifically metabolic tumour volume (MTV) and total lesion glycolysis (TLG), have been shown to be prognosticators in other malignancies, but these have not been investigated to date in NETs.

Methods: Patients with NEN undergoing PRRT at Royal North Shore Hospital who underwent FDG PET prior to therapy were retrospectively included (2012-17). Images were analysed using MIM software version 6.8.3, with automated segmentation (SUV cutoff of 4) followed by contour verification by a nuclear medicine physician and manual segmentation where required. Variables collected included patient age, WHO 2010 histological grade, MTV, TLG, and SUVmax/peak. The median MTV and TLG were used to dichotomize the cohort. The primary outcome was progression-free survival (PFS), and the secondary outcome was overall survival (OS). Survival curves were compared using the log-rank test.

Results: 49 patients were included (median age 60, 43% female). Primary site: 49% small bowel, 29% pancreas, 22% other. Grade for GEPNENs: G1 31%, G2 55%, G3 7%, unknown 7%. Median MTV was 3.15mL and TLG was 15.5. Patients with high MTV had worse median PFS compared to those with low MTV (19.7mo vs 26.6mo, HR 2.56, 95% CI 1.14-5.73, p=0.02), with the same findings for TLG (19.7mo vs 26.6mo, HR 2.56, p=0.02). Patients with higher grade disease were more likely to have high MTV (p=0.04) and TLG (p=0.04). PFS was shorter in patients with extrahepatic disease compared to those without (19.7mo vs 22.5mo, HR 2.3, 95% CI 1.004-5.4, p=0.049), but was not significantly affected by histological grade or SUVmax/peak. Overall survival was not significantly different between patients with high and low MTV (p=0.23).

Conclusions: Quantitative analysis of FDG PET in NEN is feasible. High MTV/TLG are predictors of poor prognosis in NEN. Further analyses are underway to investigate a larger cohort of NEN patients.

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 60, Issue supplement 1
May 1, 2019
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Predictors of outcome in patients with neuroendocrine neoplasm (NEN) undergoing FDG PET prior to PRRT
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Predictors of outcome in patients with neuroendocrine neoplasm (NEN) undergoing FDG PET prior to PRRT
David Chan, Paul Roach, Elizabeth Bernard, Nick Pavlakis, Stephen Clarke, Kathy Willowson, Dale Bailey, Geoff Schembri
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1514;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Predictors of outcome in patients with neuroendocrine neoplasm (NEN) undergoing FDG PET prior to PRRT
David Chan, Paul Roach, Elizabeth Bernard, Nick Pavlakis, Stephen Clarke, Kathy Willowson, Dale Bailey, Geoff Schembri
Journal of Nuclear Medicine May 2019, 60 (supplement 1) 1514;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oncology: Clinical Therapy and Diagnosis

  • Added value of single photon emission computed tomography (SPECT) / Computed Tomography (CT) with radioiodine whole body scan in follow up of patients with differentiated thyroid cancer
  • Assessment of semi-quantitative evaluation using SUV applying 2 phase-imaging of IMP SPECT for diagnosis of choroidal melanoma.
  • Surveillance Imaging of Laryngeal Cancer - Does FDG PET/CT Impact Survival?
Show more Oncology: Clinical Therapy and Diagnosis

Endocrinology (Clinical Therapy) Posters

  • External Radiation Exposure Rates After [177Lu]DOTA-Octreotate Therapy
  • Feasibility of post-therapy quantitative Lu-177-DOTATATE SPECT/CT in patients with metastatic neuroendocrine tumor for evaluation of response to treatment: Comparison with Ga68-DOTATATE-PET/CT
Show more Endocrinology (Clinical Therapy) Posters

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire